302440.KS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 02:30):

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally...

Stats
Today's Volume	44 111.00
Average Volume	76 221.00
Market Cap	4 409.91B
EPS	KRW0 ( 2024-03-15 )
Next earnings date	( KRW-245.00 ) 2024-05-09
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW66.87 (0.12%)

Volume Correlation

Long: 0.05 (neutral)

Short: 0.91 (very strong)

Signal:(63.515) Expect same movement, but be aware

SK bioscience Co.,Ltd. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SK bioscience Co.,Ltd. Correlation - Currency/Commodity

-0.35
( neutral )

-0.37
( neutral )

-0.36
( neutral )

-0.35
( neutral )

0.20
( neutral )

0.45
( neutral )

SK bioscience Co.,Ltd. Financials

Annual	2023
Revenue:	KRW369.51B
Gross Profit:	KRW136.40B (36.92 %)
EPS:	KRW290.65

FY	2023
Revenue:	KRW369.51B
Gross Profit:	KRW136.40B (36.92 %)
EPS:	KRW290.65

FY	2022
Revenue:	KRW456.73B
Gross Profit:	KRW239.61B (52.46 %)
EPS:	KRW1 596.18

FY	2021
Revenue:	KRW929.00B
Gross Profit:	KRW570.28B (61.39 %)
EPS:	KRW5 798.46

Financial Reports:

No articles found.

SK bioscience Co.,Ltd.

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.